Literature DB >> 19542124

Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family 'Porphyromonadaceae' isolated from rat faeces.

Mitsuo Sakamoto1, Akiko Takagaki, Kohei Matsumoto, Yuko Kato, Keiichi Goto, Yoshimi Benno.   

Abstract

Two bacterial strains, designated MT01(T) and MT12(T), isolated from rat faeces were characterized by using a polyphasic taxonomic approach that included analysis of their phenotypic and biochemical features, cellular fatty acid profiles, menaquinone profiles and phylogeny based on 16S rRNA gene sequences. The 16S rRNA gene sequence analysis showed that these strains were members of the family 'Porphyromonadaceae'. The strains shared 94 % 16S rRNA gene sequence similarity with each other and were related to Odoribacter splanchnicus NCTC 10825(T) (86-87 % sequence similarity). The strains consisted of obligately anaerobic, non-pigmented, non-spore-forming, non-motile, Gram-negative rods. Growth of the strains was inhibited on medium containing 20 % bile. The two strains produced significant levels of butyric and isobutyric acids as end products from glucose. Although the major cellular fatty acid of these two strains and O. splanchnicus JCM 15291(T) was iso-C(15 : 0), strains MT01(T) and MT12(T) showed a higher level of iso-C(15 : 0) (66 and 74 %, respectively) than did O. splanchnicus JCM 15291(T) (48 %). In addition, the ratios of iso-C(15 : 0) to anteiso-C(15 : 0) in whole-cell methanolysates of the two isolates were very much higher than that of O. splanchnicus JCM 15291(T). The major menaquinone of the isolates was MK-10. This menaquinone composition was different from those of other genera of the family 'Porphyromonadaceae', such as Barnesiella (predominant menaquinones: MK-11 and MK-12), Odoribacter (MK-9), Paludibacter (MK-8), Parabacteroides (MK-9 and MK-10), Porphyromonas (MK-9 and MK-10) and Tannerella (MK-10 and MK-11). Menaquinone composition is therefore an important chemotaxonomic characteristic of these micro-organisms. Strains MT01(T) and MT12(T) have DNA G+C contents of 46 mol%. On the basis of these data, strains MT01(T) and MT12(T) represent two novel species of a novel genus, for which the names Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., respectively, are proposed. The type strains of B. synergistica and B. virosa are MT01(T) (=JCM 15148(T) =CCUG 56610(T)) and MT12(T) (=JCM 15149(T)=CCUG 56611(T)), respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542124     DOI: 10.1099/ijs.0.007674-0

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  38 in total

1.  Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.

Authors:  Aimon K Alkanani; Naoko Hara; Peter A Gottlieb; Diana Ir; Charles E Robertson; Brandie D Wagner; Daniel N Frank; Danny Zipris
Journal:  Diabetes       Date:  2015-06-11       Impact factor: 9.461

2.  Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function.

Authors:  Jiaming Zhang; Fanghua Zhang; Changying Zhao; Qian Xu; Cheng Liang; Ying Yang; Huiling Wang; Yongfang Shang; Ye Wang; Xiaofeng Mu; Dequan Zhu; Chunling Zhang; Junjie Yang; Minxiu Yao; Lei Zhang
Journal:  Endocrine       Date:  2018-12-24       Impact factor: 3.633

Review 3.  Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.

Authors:  Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler
Journal:  Clin Microbiol Rev       Date:  2020-09-09       Impact factor: 26.132

4.  Analysis of 1,000 Type-Strain Genomes Improves Taxonomic Classification of Bacteroidetes.

Authors:  Marina García-López; Jan P Meier-Kolthoff; Brian J Tindall; Sabine Gronow; Tanja Woyke; Nikos C Kyrpides; Richard L Hahnke; Markus Göker
Journal:  Front Microbiol       Date:  2019-09-23       Impact factor: 5.640

5.  Social Stress Affects Colonic Inflammation, the Gut Microbiome, and Short-chain Fatty Acid Levels and Receptors.

Authors:  Ross M Maltz; Jeremy Keirsey; Sandra C Kim; Amy R Mackos; Raad Z Gharaibeh; Cathy C Moore; Jinyu Xu; Arpad Somogyi; Michael T Bailey
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-04       Impact factor: 2.839

6.  CD44 deletion leading to attenuation of experimental autoimmune encephalomyelitis results from alterations in gut microbiome in mice.

Authors:  Kumaraswamy Naidu Chitrala; Hongbing Guan; Narendra P Singh; Brandon Busbee; Alexa Gandy; Pegah Mehrpouya-Bahrami; Mitra S Ganewatta; Chuanbing Tang; Saurabh Chatterjee; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Eur J Immunol       Date:  2017-06-06       Impact factor: 5.532

Review 7.  How glycan metabolism shapes the human gut microbiota.

Authors:  Nicole M Koropatkin; Elizabeth A Cameron; Eric C Martens
Journal:  Nat Rev Microbiol       Date:  2012-04-11       Impact factor: 60.633

8.  Reduction in fecal microbiota diversity and short-chain fatty acid producers in Methicillin-resistant Staphylococcus aureus infected individuals as revealed by PacBio single molecule, real-time sequencing technology.

Authors:  J Zhao; L Nian; L Y Kwok; T Sun; J Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-28       Impact factor: 3.267

9.  Description of Gabonibacter massiliensis gen. nov., sp. nov., a New Member of the Family Porphyromonadaceae Isolated from the Human Gut Microbiota.

Authors:  Gaël Mourembou; Jaishriram Rathored; Jean Bernard Lekana-Douki; Angélique Ndjoyi-Mbiguino; Saber Khelaifia; Catherine Robert; Nicholas Armstrong; Didier Raoult; Pierre-Edouard Fournier
Journal:  Curr Microbiol       Date:  2016-09-15       Impact factor: 2.188

Review 10.  Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.

Authors:  Wei Jia; Cynthia Rajani; Hongxi Xu; Xiaojiao Zheng
Journal:  Protein Cell       Date:  2020-08-14       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.